ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Cancer
Adenocarcinoma
Stomach Cancer
Ovarian Cancer
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near Toronto, ON, CAN:

Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...

Active, not recruiting
Gastric Cancer
Pancreatic Cancer
Biological: CT041

Phase 1, Phase 2

CARsgen Therapeutics

Toronto, Ontario, Canada and 15 other locations

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety pr...

Enrolling
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Drug: AMG 193
Drug: Gemcitabine

Phase 1

Amgen
Amgen

Toronto, Ontario, Canada and 76 other locations

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...

Active, not recruiting
Non-small Cell Lung Cancer
Colorectal Neoplasms
Drug: PF-08046049

Phase 1

Seagen, a wholly owned subsidiary of Pfizer

Toronto, Ontario, Canada and 35 other locations

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agen...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: Pembrolizumab
Drug: Cetuximab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Toronto, Ontario, Canada and 7 other locations

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of th...

Enrolling
Esophageal Cancer
Pancreatic Adenocarcinoma
Drug: PF-08046876

Phase 1

Pfizer
Pfizer

Toronto, Ontario, Canada and 12 other locations

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Adv...

Enrolling
Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
Advanced Solid Tumors
Drug: WEF-001

Phase 1, Phase 2

Auricula Biosciences Inc.

Toronto, Ontario, Canada and 3 other locations

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age....

Active, not recruiting
Breast Cancer
Biliary Cancer
Drug: Camizestrant
Drug: T- Dxd

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 67 other locations

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially d...

Enrolling
Gastric Cancers
Pancreatic Cancer
Drug: BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)

Phase 1, Phase 2

Bold Therapeutics

Toronto, Ontario, Canada and 15 other locations

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors...

Active, not recruiting
Pancreatic Cancer Harboring NRG1 Fusion
NSCLC Harboring NRG1 Fusion
Drug: zenocutuzumab (MCLA-128)

Phase 2

Partner Therapeutics

Toronto, Ontario, Canada and 63 other locations

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other ...

Active, not recruiting
Stage IV Pancreatic Cancer AJCC v6 and v7
Pancreatic Ductal Adenocarcinoma
Other: 18F-Fluoromisonidazole
Drug: Cediranib Maleate

Phase 2

National Cancer Institute (NCI)
National Cancer Institute (NCI)

Toronto, Ontario, Canada and 15 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems